After observing a correlation between elevated serum lactate dehydrogenase (LDH) levels and good stem cell collections, retrospective data from 540 donors undergoing 650 stem cell apheresis procedures (87% autologous, 13% allogeneic) were studied to determine the correlation between preapheresis LDH levels and the absolute peripheral blood CD34 þ cell count (PBCD34). PBCD34 (1-1611/ll; median 40) correlated modestly with leukocytes (0.5-118.2 Â 10 9 /l; median 30.2) (r ¼ 0.16; P ¼ 0.00005) and poorly with platelets (16-660 Â 10 9 /l; median 131) (r ¼ 0.02; P ¼ 0.69). The correlation between LDH (64-1664 IU/l; median 310) and PBCD34 was very strong (r ¼ 0.54; Po10 À48 ). In multivariate regression analysis, serum LDH was the only factor correlating significantly with PBCD34. The correlation between serum LDH and PBCD34 was strong on the first day of collection (n ¼ 517; r ¼ 0.53; Po10
Introduction
The preapheresis absolute peripheral blood CD34 þ cell count (PBCD34) is the most important determinant of the number of stem cells collected during leukapheresis from patients and healthy donors. [1] [2] [3] [4] PBCD34 reflects the extent of mobilization of stem cells from the bone marrow into the blood-and depends upon a number of factors including diagnosis, extent of prior therapy, mobilization technique and type and dose of the growth factor used. 3, [5] [6] [7] [8] [9] However, PBCD34 is not always immediately available at the planned time of apheresis. Waiting for a PBCD34 result for a few hours may result in a delayed start or even a missed opportunity for a good stem cell collection. A surrogate marker that can be checked more easily and can predict an adequate level of PBCD34 may reduce the need to rely on PBCD34 in making a decision to go ahead with planned apheresis. We have previously shown that the combination of total leukocyte and platelet counts prior to apheresis can be used to predict adequate mobilization in normal donors. 4 Total lactate dehydrogenase (LDH) activity is significantly higher in marrow than in venous blood. 10 Elevated LDH is seen in patients with G-CSF-induced leukocytosis. 11 After anecdotally observing that patients undergoing apheresis were more likely to have a successful collection if their serum LDH was elevated, a retrospective review was undertaken to study the correlation between PBCD34 and LDH.
Patients and methods

Patients
Of 2064 stem cell harvests done on Cobe Spectra machines on patients with hematologic malignancies (plasma cell dyscrasias, lymphoma and leukemia) or their donors between March 2001 and November 2006, 650 harvests had concomitant serum LDH levels available from preapheresis blood samples. Laboratory parameters including complete blood count and PBCD34 were obtained prior to each apheresis procedure. The data were analyzed retrospectively after approval from the Institutional Review Board. The 650 harvests represented 540 unique patients (87%; autologous) or donors (13%; allogeneic). The mobilization regimen comprised of single-agent G-CSF at a dose of 10-12 mg/kg per day for allogeneic collections, and single-agent G-CSF at a dose of 12-18 mg/kg per day or a combination of chemotherapy and growth factor for autologous collections.
Leukapheresis
Cobe Spectra cell separators (Gambro BCT, Lakewood, CO, USA) running the semi-automated mononuclear cell collection protocol (Version 6.1) according to the manufacturer's recommendations were used for leukapheresis. Large volume leukapheresis was performed at a blood flow rate of 70-100 ml/min. The blood volume processed was o15 l in 6%, 15-19 l in 14%, and 20 l in 80%. The apheresis product was analyzed in the stem cell processing laboratory to determine the hematocrit, platelet count, mononuclear cell count, CD34 þ cell count and the CD34 þ collection efficiency.
Statistical analysis
For the purposes of analysis, each individual apheresis procedure was considered a separate event. The first (n ¼ 517) and second (n ¼ 74) day's apheresis procedures for each unique patient/donor were analyzed separately from procedures beyond the second day (n ¼ 59) to account for apheresis-induced depletion of LDH. The disparity between the number of day 1 procedures and the number of unique patients/donors is because some mobilizationcollection episodes did not have a concomitant LDH level available on the first day but an LDH level was available subsequently. The data were analyzed for correlation, and univariate and multivariate regression using Excel 2003 for Windows. The w 2 test was used to compare categoric groups.
The factors analyzed by multivariate regression analysis for their correlation with PBCD34 were the preapheresis hematocrit, leukocyte count, platelet count and LDH. The aim was to find a surrogate marker for PBCD34 rather than factors affecting stem cell mobilization-and thus factors likely to affect mobilization such as diagnosis, the nature of prior therapy, mobilization technique and growth factor dose were not analyzed. Table 1 shows counts, cell yields and biochemical parameters. PBCD34 correlated modestly with the total leukocyte count (r ¼ 0.16; P ¼ 0.00005) and poorly with the platelet count (r ¼ 0.02; P ¼ 0.69).
Results
The correlation between serum LDH and PBCD34 was very strong (r ¼ 0.54; Po10 À48 ) (Figure 1 ). The correlation between serum LDH and PBCD34 was very strong on the first day of collection (n ¼ 517; r ¼ 0.53; Po10
À37
). The relationship weakened to some extent on the second day (n ¼ 74; r ¼ 0.37; P ¼ 0.0009), and disappeared entirely after the second day (n ¼ 59; r ¼ 0.09; P ¼ 0.49). The relationship between LDH and PBCD34 was stronger for autologous (r ¼ 0.54; Po10
À42
) than for allogeneic (r ¼ 0.41; P ¼ 0.00009) collections.
Overall, the likelihood of poor mobilization (PBCD34 o5/ml) was small when LDH was elevated-and was negligible when the LDH was more than twice the upper limit of normal. This relationship was strongest on day 1 and then weakened afterwards (Table 2) .
While there was good correlation between the total leukocyte count and LDH (r ¼ 0.34; Po10 À17 ), this was not as strong as that between PBCD34 and LDH (r ¼ 0.54; Po10
À48
). The relationship between PBCD34 and LDH level was strong across different leukocyte count ranges (Table 3 ; upper panels). On the other hand, the relationship (n ¼ 650; logarithmic scale).
Table 2
Relationship between LDH and PBCD34 by day of apheresis LDH level (IU/l) n PBCD34 (% of patients) o5/ml o10/ml o20/ml between the total leukocyte count ranges and PBCD34 independent of LDH was modest (Table 3 ; lowermost panel). The predictive value of LDH was good when stem cells were mobilized with G-CSF alone (n ¼ 246; r ¼ 0.45; Po10
À11
) or with the combination of chemotherapy and G-CSF (n ¼ 404; r ¼ 0.55, Po10 À31 ). As expected, there was very strong correlation between PBCD34 and the number of CD34 þ cells collected (r ¼ 0.93; Po10
À288
). On the other hand, the correlation between the total leukocyte count and the number of CD34 þ cells collected was poor (r ¼ 0.10; P ¼ 0.013). The correlation between LDH and the number of CD34 þ cells collected was strong (r ¼ 0.51; Po10 À42 ).
Discussion
Our data suggest that there is significant correlation between serum LDH and the number of circulating CD34 þ cells, with elevated LDH being an excellent surrogate marker of good stem cell mobilization. Cell proliferation is known to result in elevated LDH. 12 Therefore, it was not unexpected to see a significant correlation between LDH and the total leukocyte count. However, the relationship between CD34 þ cell numbers in the blood and LDH was far stronger. This suggests that while a greater part of the leukocytosis seen in response to G-CSF is redistribution of cells between the marrow and blood compartments, the increase in the number of circulating CD34 þ cells is largely due to cell proliferation. The decision to increase the dose of G-CSF during an unsuccessful or partly successful stem cell collection is often governed by the extent of leukocytosis. Growth factor dose is rarely increased in patients whose total leukocyte count is already high (for example 450 Â 10 9 /l). Based on our data, one could argue that in patients with leukocytosis but low LDH levels, it may be possible to improve PBCD34 by increasing the myeloid growth factor dose despite leukocytosis. Our data are insufficient to answer this question.
In practical terms, because a high LDH is likely to be associated with good PBCD34 (and thus a good stem cell collection), apheresis can be started without necessarily awaiting flow cytometry results to confirm the PBCD34 number. This is especially important for facilities where real-time CD34 þ cell counts are difficult to obtain. Conversely, if leukocytosis is seen without elevated LDH, the chances of a good PBCD34 count are small-and it may be prudent to await flow cytometry results before deciding to proceed with apheresis.
In summary, our data suggest that serum LDH is the strongest known surrogate marker of circulating CD34 þ cells after mobilization with growth factors with or without added chemotherapy in both autologous and healthy donors. Table 3 Relationship between LDH levels and PBCD34 for different leukocyte count ranges 
